NICE publishes guidance for atopic dermatitis treatments

pharmafile | April 8, 2022 | News story | Medical Communications  

Abrocitinib, upadacitinib, and tralokinumab are not recommended for treating moderate to severe atopic dermatitis. The recommendation does not affect patients who are already using these treatments.

The standard-of-care treatments currently available to patients with atopic dermatitis, include topical treatments such as creams and corticosteroids. If these treatments are not effective, systemic immunosuppressants such as methotrexate and ciclosporin can also be used, and if these are not effective, targeted systematic therapies like dupilumab and baricitinib can be used. Phototherapy can also be effective if a person has severe dermatitis.

NICE recognises that there is a lack of treatments for people who do not respond to current available treatments, or are unable to tolerate them.

The clinical trial evidence shows that abrocitinib, upadacitinib, and tralokinumab all reduce symptoms of atopic dermatitis when compared to placebo. However, comparing the effectiveness of the drugs against treatments that are already available was highly uncertain.

Atopic dermatitis is a condition that affects the skin, and is one of the most common skin disorders in children. Patients suffering from atopic dermatitis have dry, inflamed skin which can cause severe itchiness. Treatments are targeted towards providing symptom relief and controlling symptoms in the longer term.

The limitations in current clinical trial evidence mean the results from the economic model are also highly uncertain, meaning that it is difficult to determine the cost-effectiveness of the drugs.  

Lina Adams

Related Content

No items found

Latest content